Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

One-Time gene infusion aims to save babies from devastating muscle disease

NCT ID NCT03837184

Summary

This study tested a single-dose gene replacement therapy for babies under 6 months old with a severe form of spinal muscular atrophy (SMA Type 1). The main goal was to see if the treatment could help these infants achieve the milestone of sitting up on their own for at least 10 seconds by 18 months of age. The therapy, delivered through a one-hour IV infusion, aims to address the genetic root cause of the disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SPINAL MUSCULAR ATROPHY TYPE I are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Pusan National University Yangsan Hospital

    Yangsan, Gyeongsangnam-do, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Tokyo Women's Medical University

    Tokyo, Japan

Conditions

Explore the condition pages connected to this study.